EcoR1 Capital, LLC recently filed their 13F report for the second quarter of 2022, which ended on 2022-06-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
357 TEHAMA STREET #3 SAN FRANCISCO, CA 94103
As of the latest 13F report, the guru’s equity portfolio contained 80 stocks valued at a total of $2.90Bil. The top holdings were PRTA(10.86%), APLS(8.09%), and SRPT(7.42%).
According to GuruFocus data, these were EcoR1 Capital, LLC’s top five trades of the quarter.
Voyager Therapeutics Inc
During the quarter, EcoR1 Capital, LLC bought 491,507 shares of NAS:VYGR for a total holding of 4,753,907. The trade had a 0.09% impact on the equity portfolio. During the quarter, the stock traded for an average price of $5.58.
On 08/16/2022, Voyager Therapeutics Inc traded for a price of $6.02 per share and a market cap of $232.66Mil. The stock has returned 103.38% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Voyager Therapeutics Inc has a price-book ratio of 3.89, a EV-to-Ebitda ratio of -2.03 and a price-sales ratio of 7.38.
The price-to-GF Value ratio is 1.25, earning the stock a GF Value rank of 6.
Revolution Medicines Inc
During the quarter, EcoR1 Capital, LLC bought 3,032,403 shares of NAS:RVMD for a total holding of 4,306,500. The trade had a 1.57% impact on the equity portfolio. During the quarter, the stock traded for an average price of $16.8.
On 08/16/2022, Revolution Medicines Inc traded for a price of $25.84 per share and a market cap of $2.27Bil. The stock has returned 1.10% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10. There is insufficient data to calculate the stock’s profitability rating.
In terms of valuation, Revolution Medicines Inc has a price-book ratio of 3.86, a EV-to-Ebitda ratio of -8.65 and a price-sales ratio of 70.22.
Arvinas Inc
During the quarter, EcoR1 Capital, LLC bought 1,633,101 shares of NAS:ARVN for a total holding of 3,137,030. The trade had a 2.28% impact on the equity portfolio. During the quarter, the stock traded for an average price of $45.68.
On 08/16/2022, Arvinas Inc traded for a price of $54.12 per share and a market cap of $2.88Bil. The stock has returned -40.66% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Arvinas Inc has a price-book ratio of 4.30, a EV-to-Ebitda ratio of -6.98 and a price-sales ratio of 31.27.
The price-to-GF Value ratio is 0.60, earning the stock a GF Value rank of 8.
Sarepta Therapeutics Inc
The guru established a new position worth 2,069,634 shares in NAS:SRPT, giving the stock a 5.06% weight in the equity portfolio. Shares traded for an average price of $76.46 during the quarter.
On 08/16/2022, Sarepta Therapeutics Inc traded for a price of $109.04 per share and a market cap of $9.55Bil. The stock has returned 36.40% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Sarepta Therapeutics Inc has a price-book ratio of 13.12, a EV-to-Ebitda ratio of -22.06 and a price-sales ratio of 11.13.
The price-to-GF Value ratio is 0.83, earning the stock a GF Value rank of 9.
Nuvation Bio Inc
The guru sold out of their 13,896,543-share investment in NYSE:NUVB. Previously, the stock had a 3.76% weight in the equity portfolio. Shares traded for an average price of $5.86 during the quarter.
On 08/16/2022, Nuvation Bio Inc traded for a price of $5.445 per share and a market cap of $1.19Bil. The stock has returned -49.55% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, Nuvation Bio Inc has a price-book ratio of 1.58 and a EV-to-Ebitda ratio of -12.19.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
